Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in the company's Ordinary Shares, filed pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding executive compensation and does not contain financial performance data.
Material Changes
The filing details a specific transaction involving Mr. S A Hussain, a Person Discharging Managerial Responsibility. On June 2, 2012, 50% of an award made on June 2, 2008, under the GlaxoSmithKline Deferred Investment Award Plan vested. Consequently, Mr. Hussain received a cash payment in respect of 22,208.788 notional Ordinary Shares. The payment was calculated based on a share price of £14.22 per Ordinary Share as of June 1, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the PDMR transaction described above.
Key Facts for Investor Verification
- Transaction Type: Vesting of a Deferred Investment Award Plan.
- Individual Involved: Mr. S A Hussain (Person Discharging Managerial Responsibility).
- Share Count: 22,208.788 notional Ordinary Shares.
- Valuation Basis: £14.22 per Ordinary Share (as of June 1, 2012).
- Payment Form: Cash payment.
- Notification Date: June 6, 2012.